Tim Smith

This post-hoc analysis highlights nemolizumab’s long-term efficacy and safety in adolescents with moderate-to-severe atopic dermatitis.

Following the Skin of Color Society's (SOCS) 8th Annual Media Day, a Skin of Color Savvy podcast episode will be released highlighting the event.

The Psoriasis Study of Health Outcomes (PSoHO) was designed as a 36-month, non-interventional, international cohort study of patients with psoriasis.

In this analysis, investigators examined the efficacy of baricitinib in terms of its impact on disease activity and progression of frontal fibrosing alopecia.

These data highlight a super-response following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe CHE.

The SCALE-UP study, assessing patients with atopic dermatitis treated with upadacitinib, points to rapid real‐world efficacy findings on this medication.

At the Fall Clinical Dermatology Conference, this session provided clinical pearls to clinicians in the pediatric dermatology space.

These topline results from the ADHAND trial highlight tralokinumab’s use in adults with atopic dermatitis with moderate-to-severe hand involvement.

The FDA acceptance of Arcutis's supplemental New Drug Application (sNDA) was announced for roflumilast cream 0.3% (Zoryve).

In a session presented at the SDPA Fall Conference, Karan Lal, DO, spoke on the topic of GLP-1 agonist drugs for weight loss and their connection to dermatology.

In a session presented at the 2025 SDPA Fall Conference, a review was given of common genetic syndromes with cutaneous manifestations.

At the 2025 SDPA Fall Conference, Laura Bush, DMSc, PA-C, presented the next iteration of an IMID and Obesity bootcamp session.

This study demonstrates the impact of an elastic scattering spectroscopy (ESS) device, owned by DermaSensor, on melanoma assessment in primary care settings.

These phase 4 data from the UnlIMMited trial highlight the efficacy and safety of risankizumab for psoriasis in the genital or scalp region.

In the CHECK study, a cross-sectional survey of over 10,000 participants, the prevalence of chronic hand eczema (CHE) in the US was highlighted.

These recent findings on roflumilast cream (Zoryve) highlight the topical agent’s efficacy and impacts on quality of life in younger patients with atopic dermatitis.

Once-daily oral baricitinib was shown to result in meaningful hair regrowth after 1 year in adolescent patients with alopecia areata.

Lilly's lebrikizumab-lbkz treatment, used once every 8 weeks, resulted in durable disease control in moderate-to-severe atopic dermatitis.

This systematic review and meta-analysis highlights tildrakizumab’s efficacy in Asian patients versus the efficacy of other biologic options.

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

This analysis highlights the impact of dermatology consultations on HS management within acute care settings.

SelectION, Inc. has announced positive topline findings from its phase 1b proof-of-concept study assessing si-544 in those with psoriasis vulgaris.

JAK inhibitors have transformed the world of treatment for inflammatory disease, and views on their safety and efficacy have also transformed over the years.

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical announced these new findings on RPT904 (JYB1904) in chronic spontaneous urticaria.

Investigators synthesized existing data on psychiatric comorbidities and outcomes related to quality of life in pediatric vitiligo.

This systematic review and network meta-analysis was conducted to establish a hierarchy among approved oral JAK inhibitors for severe alopecia areata in adults.

This systematic review and meta-analysis of available randomized controlled trials compared biologics for psoriasis, such as ixekizumab, secukinumab, and ustekinumab.

These post hoc findings suggest psychosocial burden may improve following hair regrowth with ritlecitinib.

In this analysis, investigators validated the Automatic Psoriasis Area and Severity Index (APASI), an AI-driven system for psoriasis severity assessment.